Supernus Pharmaceuticals ...

NASDAQ: SUPN · Real-Time Price · USD
42.49
0.32 (0.76%)
At close: Aug 15, 2025, 9:54 AM

Supernus Pharmaceuticals Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
69.33M 75.05M 93.12M 203.43M
Short-Term Investments
384.28M 179.82M 368.21M 136.25M
Long-Term Investments
n/a 16.62M 93.9M 119.17M
Other Long-Term Assets
31.53M 8.51M -10M -36.12M
Receivables
142.08M 144.16M 165.5M 148.93M
Inventory
54.29M 77.41M 91.54M 85.96M
Other Current Assets
36.09M 16.68M 15.78M 27.02M
Total Current Assets
686.07M 493.11M 734.15M 601.59M
Property-Plant & Equipment
11.54M 42.52M 15.17M 16.95M
Goodwill & Intangibles
638.93M 716.91M 819.48M 902.21M
Total Long-Term Assets
682M 784.56M 968.36M 1.09B
Total Assets
1.37B 1.28B 1.7B 1.69B
Account Payables
4.59M 1.96M 10.54M 9.33M
Deferred Revenue
n/a n/a 49.81M 126.25M
Short-Term Debt
n/a n/a 401.97M 7.24M
Other Current Liabilities
100.72M 259.18M 251.69M 92.86M
Total Current Liabilities
292.4M 290.2M 687.96M 315.38M
Long-Term Debt
n/a n/a n/a 379.25M
Other Long-Term Liabilities
7.6M 7.8M 42.54M 52.02M
Total Long-Term Liabilities
39.94M 65.96M 128.35M 557.92M
Total Liabilities
332.34M 356.16M 816.3M 873.3M
Total Debt
34.27M 41.53M 437.97M 420.55M
Common Stock
56K 55K 54K 53K
Retained Earnings
556.43M 482.56M 481.25M 379.92M
Comprehensive Income
-189K -593K -3.21M 1.54M
Shareholders Equity
1.04B 921.52M 886.2M 815.85M
Total Investments
384.28M 196.44M 462.11M 255.41M